It explains the State Farm agent experience with a flow chart of agent progression through the program, and includes agent testimonials. The brochure does not include any test questions, but the website may be used to find local agents who may be willing to share some tips.
The secondary objectives are safety profile and the response rate. Lapatinib, an oral inhibitor of EGFR and HER2, have been shown to be an effective treatment in HER2/neu overexpressing metastatic breast cancer patient who refractory herceptin, taxane, and anthracycline treatment.
The approval was based on a randomized controlled trial of sunitinib, 37.5 mg by mouth daily (n=86), versus placebo (n=85) in patients with unresectable, locally advanced, or metastatic well-differentiated pNET. Treatment with somatostatin analogs was allowed.n additional patient treated with sunitinib was taken off study due to cardiac failure and died two months later. Adverse events resulted in permanent discontinuation of treatment in 22 percent of patients treated with sunitinib and 17 percent of patients treated with placebo.